News

Taiwan News5h

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with ...

Your ultimate guide to travelling with fat jabs – from costly mistakes to nasty side effects & rules to avoid disaster

WEIGHT loss jabs are weaving themselves into the fabric of our daily lives and chances are you know someone taking them – or ...